Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib in Tumors With CDK4 or CDK6 Amplification (MATCH Subprotocol Z1C)
NCT06390839Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2017
- Primary completion
- Jan 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of palbociclib in lymphoma, malignant solid neoplasm, sponsored by National Cancer Institute. Started Mar 2017; status: active, not recruiting.
02
Drugs
palbociclib
03
Conditions
lymphomamalignant solid neoplasm
Beyond the preview
Go deeper on NCT06390839.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390839.